Evidence map›Paper›PMID 40216677›Full record

ArticleDoklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections2025

Targeted Therapy in Combination with an Agent That Enhances Terminal Differentiation of Cancer Cells.

E I Shramova, G M Proshkina, I N Zavestovskaya, S M Deyev

Abstract read
PubMed Publisher
In one paragraph

Article in Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

E I ShramovaShemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia. shramova.e.i@gmail.com.
G M ProshkinaShemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
I N ZavestovskayaLebedev Physical Institute, Russian Academy of Sciences, Moscow, Russia.
S M DeyevShemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, in addition to standard methods, an approach is being developed for the treatment of oncological diseases in which terminal differentiation of cancer cells is induced by pharmacological drugs, which increases the response to traditional treatment methods. According to literature data, dimethyl sulfoxide (DMSO) is a safe adjuvant that stimulates the differentiation of various types of the cancer cells. A method proposed in the article was designed to eliminate SKOV3.ip1 human ovarian cancer cell adenocarcinomas by combining targeted therapy based on the HER2-specific toxin DARPin-LoPE and treatment with DMSO as an enhancing agent for terminal differentiation of cancer cells.

Indexed as

Cell DifferentiationDimethyl SulfoxideOvarian NeoplasmsCell Line, TumorErb-b2 Receptor Tyrosine KinasesFemaleHumansDimethyl SulfoxideERBB2 protein, humanErb-b2 Receptor Tyrosine Kinasescancer cell differentiationcombination therapydimethyl sulfoxideovarian adenocarcinomatargeted toxins

Identifiers

PMID40216677

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.